Stocks and InvestingStocks and Investing
Mon, October 31, 2022
Sun, October 30, 2022
Fri, October 28, 2022

Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $285 on, Oct 28th, 2022


Published on 2024-10-27 23:44:27 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $253 to $285 on, Oct 28th, 2022.

Matthew has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 3 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Do Kim of "Piper Sandler" Maintained at Hold with Increased Target to $288 on, Wednesday, August 17th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold and Held Target at $263 on, Wednesday, August 10th, 2022
  • Brian Skorney of "Baird" Maintained at Hold and Held Target at $250 on, Friday, August 5th, 2022


These are the ratings of the 4 analyists that currently disagree with Matthew


  • Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $327 on, Monday, October 24th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $337 on, Friday, October 21st, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Friday, August 5th, 2022
  • Olivia Brayer of "Cantor Fitzgerald" Initiated at Buy and Held Target at $365 on, Wednesday, July 13th, 2022